Strong Development Pipeline

A diverse pipeline designed to address significant unmet medical needs

We are focused on developing a new generation of targeted, empowered therapies with the goal of advancing the foundation of care. In addition to a comprehensive development program to further expand ADCETRIS® (brentuximab vedotin), our robust pipeline is designed to address significant unmet medical needs.

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

Brentuximab Vedotin

Hodgkin Lymphoma (HL)

Target: CD30

Technology Platform: ADC using MMAE

Collaborator:

Frontline HL in patients ≥ 60 (+ nivolumab)

Enrolling

Second-line HL (+ nivolumab)

Enrolling

CheckMate 744: Relapsed cHL (+ nivolumab)

Enrolling

Late-Stage Programs

Target: Nectin-4

Technology Platform: ADC using MMAE

Collaborator:

EV-301: Urothelial cancer post PD(L)-1 inhibitor


EV-201: Urothelial cancer post PD(L)-1 inhibitor

Topline results of cohort 1 announced / Pivotal / Enrolling

EV-103: First-line urothelial cancer (+ pembrolizumab and/or chemotherapy)

Enrolling

Target: HER2

HER2CLIMB-02: HER2-positive breast cancer (+ T-DM1)

Enrolling

HER2CLIMB: HER2-positive breast cancer

Pivotal / enrollment complete

MOUNTAINEER: Colorectal cancer (+ trastuzumab)

Enrolling

I-SPY 2: Neoadjuvant breast cancer

Enrolling

Target: Tissue factor

Technology Platform: ADC using MMAE

Collaborator:

innovaTV 204: Recurrent cervical cancer

Pivotal

innovaTV 205: Recurrent cervical cancer

Enrolling

innovaTV 207: Other solid tumors

Enrolling

innovaTV 208: Ovarian cancer

Enrolling

Early-Stage Programs

Target: LIV-1

Technology Platform: ADC using MMAE

I-SPY 2: HER2-negative breast cancer

Enrolling

Triple negative breast cancer (TNBC) (+ pembrolizumab)

Enrolling

MORPHEUS: TNBC (+ atezolizumab)

Enrolling

Breast cancer

Enrolling

SEA-BCMA

Target: BCMA

Technology Platform: Sugar engineered Antibody (SEA) technology designed to enhance antibody effector function

Multiple myeloma

Enrolling